← Back

Alzamend Neuro Inc

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing products for neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which combines lithium, proline, and salicylate for the treatment of Alzheimer's disease, bipolar disorder, post-traumatic stress disorder, major depressive disorder, and other neurodegenerative and psychiatric conditions. It also includes ALZN002, a cell-based therapeutic vaccine using mutant-peptide sensitized cells intended to restore a patient's immune response against Alzheimer's disease. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Country

USA

Sector

Biotechnology

Themes

Neuroscience & Neurodegenerative

Price · split & dividend adjusted

News & notes moving ALZN

ALZN▲

Alzamend Neuro Regains Nasdaq Listing Compliance

Alzamend Neuro has regained compliance with Nasdaq listing standards, according to a notification letter from Nasdaq dated September 14, 2026. The notice informed the company that it now complies with the equity rule, and Nasdaq stated the matter is now closed. The notification resolves the listing deficiency for the biopharmaceutical company, whose shares trade under the ticker ALZN.

ALZN ▲

Seeking Alpha·2dRead more →